Purpose: The FDA-issued PLATO trial dataset revealed that some primary
deaths causes (PDC) were inaccurately reported favoring ticagrelor.
However, the PLATO Investigators operated the shorter death list of
uncertain quality. We compared if PDC match when trial fatalities were
reported to the FDA and by the PLATO investigators. Method: The FDA list
contains precisely detailed 938 PLATO deaths, while shorter
investigators dataset consists of 905 deaths. We matched 4 vascular
(sudden, post-MI, heart failure and stroke), and 3 non-vascular (cancer,
sepsis and suicide) PDC between death lists. Results: There were more
sudden deaths in the shorter list than in the FDA dataset (161 vs.138;
p<0.03), post-AMI (373 vs.178; p<0.001) but fewer
heart failure deaths (73 vs.109; p=0.02). Stroke numbers match well (39
vs. 37; p=NS) with only 2 ticagrelor cases removed. Cancer matched well
(32 vs.31; p=NS), and sepsis cases were identical (30 vs. 30; P=NS).
However, 2 extra clopidogrel suicides in the shorter list are impossible
to comprehend. Conclusions: The PLATO trial PDC were mismatched between
FDA and Investigators sets. We are kindly asking the ticagrelor sponsor
or/and concerned PLATO Investigators to clarify the PDC dataset match.